Merck & Co. Inc. (MRK)
-NYSE 47.16 
0.17(0.36%) 4:00PM EDT|After Hours
:
47.20 0.04 (0.08%) 5:49PM EDT
| Prev Close: | 47.33 |
|---|
| Open: | 47.05 |
|---|
| Bid: | 47.28 x 100 |
|---|
| Ask: | 47.44 x 200 |
|---|
| 1y Target Est: | 50.11 |
|---|
| Beta: | 0.39 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 46.60 - 47.16 |
|---|
| 52wk Range: | 37.02 - 48.79 |
|---|
| Volume: | 15,795,941 |
|---|
| Avg Vol (3m): | 17,398,600 |
|---|
| Market Cap: | 142.40B |
|---|
| P/E (ttm): | 24.06 |
|---|
| EPS (ttm): | 1.96 |
|---|
| Div & Yield: | 1.72 (3.70%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why Immunotherapy Stocks Could Be Set for a Big Moveat Motley Fool(Fri 2:10PM EDT)
- McDonald’s Heckled At Shareholder Meeting and 2 Other Dow Movers to Watchat Wall St. Cheat Sheet(Fri 1:58PM EDT)
- Merck Halts Parkinson's Drug Trialsat Motley Fool(Fri 1:23PM EDT)
- Merck Stock Is a Good Investment (According to Merck)at Motley Fool(Fri 12:44PM EDT)
- Lessons from the best commencement speakersat Fortune(Fri 12:09PM EDT)
- In denial: Corporate America's blindness to gender discriminationat Fortune(Fri 12:03PM EDT)
- Merck & Co Inc Stock Buy Recommendation Reiterated (MRK)at TheStreet(Fri 10:05AM EDT)
- Stocks to Watch: Abercrombie, Infloblox, Pandoraat The Wall Street Journal(Fri 9:02AM EDT)
- Boy Scouts of America votes to end century-old ban on gay scoutsat Reuters(Thu, May 23)
- Merck Insomnia Drug Safe Only in Low Dosesat Bloomberg(Thu, May 23)
- Unclear Future for Merck's Insomnia Drugat Motley Fool(Thu, May 23)
- Merck halts development of experimental Parkinson's drugat Reuters(Thu, May 23)
- Merck ends development of Parkinson's disease drugAP(Thu, May 23)
- InPlay: Merck provides update on Phase 3 clinical program for preladenant, co's invetigational Parkinson's disease medicine: initial review of data from three separate trials did not provide evidence of efficacy for preladenantBriefing.com(Thu, May 23)
- Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease MedicineBusiness Wire(Thu, May 23)
Key Statistics
| Forward P/E (1 yr): | 12.51 |
|---|
| P/S (ttm): | 3.09 |
|---|
| Ex-Dividend Date: | 13-Mar-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.50 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.84 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 4.43 |
|---|
Business Summary
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
View More